After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Jan 27 (Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai (4523.T), opens new tab and partner Biogen's (BIIB.O), opens new tab Alzheimer's ...

Jan 27 (Reuters) - Sage Therapeutics (SAGE.O), opens new tab said on Monday that its board has unanimously rejected Biogen’s (BIIB.O), opens new tab $469 million offer, stating it "significantly ...

That’s the message Biogen chief executive Chris Viehbacher conveyed to Governor Maura Healey, during a Q&A session following her speech on Thursday at an Associated Industries of Massachusetts ...

Biogen is to call on the cutting-edge world of quantum computing to help speed up drug discovery. Quantum technology is one of the most exciting emerging developments in computing, and harnesses ...

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

The two companies have been partnered on Samsung Bioepis for the best part of a decade, successfully bringing six biosimilar copies of biologic drugs to regulatory approval, but Biogen now says it ...

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

Biogen has decided to close down its digital health unit, formed just two years ago, as part of a major cost-reduction drive that has already claimed thousands of jobs. The decision – first ...